English
Home > Products > 1510832-19-5

China 1510832-19-5 Factory

We've been convinced that with joint efforts, the enterprise between us will bring us mutual benefits. We are able to assure you product or service quality and aggressive cost for 1510832-19-5,CAS NO 1510832-19-5,Relebactam intermediate,Relebactam advance intermediate,tert-butyl 4-((2S,5R)-5-(benzyloxyamino), We adhere towards the tenet of "Services of Standardization, to fulfill Customers' Demands".
1510832-19-5, With the goal of "zero defect". To care for the environment, and social returns, care employee social responsibility as own duty. We welcome friends from all over the world to visit and guide us so that we can achieve the win-win goal together.

Related Products

Hot Products

  • 6-Chloro-3-Methyluracil

    6-Chloro-3-Methyluracil

    6-Chloro-3-Methyluracil
    CAS NO:4318-56-3​
    Molecular Formula:C₅H₅ClN₂O₂
    Molecular Weight:160.56
    Usage:Alogliptin Intermediates
  • (S,S)-2,3-Butanediol

    (S,S)-2,3-Butanediol

    Product Name:(S,S)-2,3-Butanediol
    Molecular Formula:C4H10O2
    Molecular Weight:90.12
    CAS Registry Number:19132-06-0
  • Diosmin

    Diosmin

    Product Name:Diosmin
    Molecular Formula:C28H32O15
    Molecular Weight;608.54
    CAS Registry Number;520-27-4
  • 2-Chloro-5-fluoronicotinic acid

    2-Chloro-5-fluoronicotinic acid

    Product Name:2-Chloro-5-fluoronicotinic acid
    Molecular Formula:C6H3ClFNO2
    Molecular Weight:175.54
    CAS Registry Number:38186-88-8
  • Carbidopa Monohydrate

    Carbidopa Monohydrate

    Product Name:Carbidopa Monohydrate
    Molecular Formula:C10H16N2O5
    Molecular Weight;244.24
    CAS Registry Number;38821-49-7
  • Ethyl nicotinate

    Ethyl nicotinate

    Product Name:Ethyl nicotinate
    Molecular Formula:C8H9NO2
    Molecular Weight:151.16
    CAS Registry Number:614-18-6
  • Related Blog
  • Reviews

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    Here are so many diseases that affect the human population in the current hours and so are the numerous drugs that are available to treat those diseases.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 1510832-19-5

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept